PRTA offers a high-asymmetry setup with a large modeled upside and active insider buying, but weak fundamental quality, including heavy cash burn and a low Piotroski score, plus a justified elevated short interest, keep the position speculative.
Thesis pillars
- High Asymmetry Favorable Setup↓Deteriorating
- Large Analyst Upside Target↓Deteriorating
- Weak Piotroski Cash Burn Quality↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
Prothena Corporation plc (PRTA) Stock Analysis
Recovery setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $9.26: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 8.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Below-average business quality; Below long-term trend.
Prothena Corporation is a late-stage clinical biotechnology company developing antibody therapies that target misfolded proteins underlying neurodegenerative and rare peripheral amyloid diseases. All four of its active clinical programs are partnered with large pharmaceutical... Read more
Sell if holding. Engine safety override at $9.26: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 8.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 58. Score 5.3/10, moderate confidence.
Passes 8/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 83d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Prothena Corporation plc
About Prothena Corporation plc
Prothena's most advanced program, prasinezumab, entered the Phase 3 PARAISO trial in the fourth quarter of 2025, testing the antibody in roughly 900 people with early Parkinson's disease under a worldwide collaboration with Roche. Two more late-stage partnered programs — coramitug for ATTR amyloidosis with cardiomyopathy in Novo Nordisk's Phase 3 CLEOPATTRA trial, and BMS-986446 for early Alzheimer's disease in Bristol Myers Squibb's Phase 2 TargetTau-1 trial — round out Prothena's clinical portfolio.
Prothena's revenue model is built on collaboration economics rather than product sales: every active clinical program is partnered with a large pharmaceutical company that funds and runs the trial, leaving Prothena eligible for milestone payments and royalties rather than direct commercial risk. Bristol Myers Squibb alone backs two programs, BMS-986446 and the Phase 1 asset PRX019, under what the company describes as two global licensing deals covering neurodegenerative diseases, while Novo Nordisk acquired Prothena's ATTR amyloidosis business outright to advance coramitug. Internally, Prothena is applying its proprietary CYTOPE technology — designed to reach previously undruggable intracellular disease targets inside neurons — to wholly owned discovery-stage programs including an anti-pTDP-43 candidate for ALS and PRX012-TfR for Alzheimer's disease, positioning those assets as the next generation of potential partnership or licensing deals.
Show full overview
Prasinezumab's path to Phase 3 rests on a Phase 2b PADOVA result that fell just short of conventional statistical significance on its primary endpoint (hazard ratio 0.84, nominal p=0.0657), with a clearer signal only in the pre-specified subgroup on levodopa (p=0.0431); Roche nonetheless advanced the antibody into the roughly 900-patient PARAISO trial in the fourth quarter of 2025. That gap between a supportive-but-inconclusive mid-stage readout and a fully powered pivotal trial is the central binary risk for Prothena's most advanced program, since the company's key research operations sit in the earthquake-prone San Francisco Bay Area and it does not carry earthquake insurance covering a facility disruption.
See also: Healthcare · Biotechnology
From Prothena Corporation plc's most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-08-14Recent Developments — Prothena Corporation plc
Latest news
- NEWS CORRECTION: Prothena Corp Q2 EPS $(0.36) Misses $(0.09) Estimate, Sales $1.010M Miss $28.295M Estimate — benzinga Aug 7, 2026 negative
- NEWS Prothena Corp Q2 EPS $0.36 Beats $(0.09) Estimate, Sales $1.010M Miss $28.295M Estimate — benzinga Aug 6, 2026 positive
- NEWS 12 Health Care Stocks Moving In Tuesday's Pre-Market Session — benzinga Jul 21, 2026 neutral
- NEWS Why Crown Holdings Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket — benzinga Jul 21, 2026 neutral
Generated 2026-08-14T12:42:25Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Unprofitable operations — net margin -80.7%. Quality floor flags this regardless of sector context.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $9.26: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 8.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 58. Prior stop was $8.44. Score 5.3/10, moderate confidence.
Take-profit target: $18.62 (+105.0% upside). Prior stop was $8.44. Stop-loss: $8.44.
Quality below floor (1.8 < 4.0); Value-trap signals (2/5): Material insider selling (38 sells, 0.25% of cap), Negative free cash flow.
Prothena Corporation plc trades at a P/E of N/A (forward -6.0). TrendMatrix value score: 7.2/10. Verdict: Sell.
12 analysts cover PRTA with a consensus score of 3.8/5. Average price target: $21.
What does Prothena Corporation plc do?Prothena Corporation is a late-stage clinical biotechnology company developing antibody therapies that target misfolded...
Prothena Corporation is a late-stage clinical biotechnology company developing antibody therapies that target misfolded proteins underlying neurodegenerative and rare peripheral amyloid diseases. All four of its active clinical programs are partnered with large pharmaceutical companies — prasinezumab with Roche (Phase 3), coramitug with Novo Nordisk (Phase 3), and BMS-986446 and PRX019 with Bristol Myers Squibb — funding development through milestones and royalties rather than product sales.